Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma

Oncotarget

Volumn 8, Issue 28, 2017, Pages 45825-45836

  Farshchian, Mehdi ^a,b   Nissinen, Liisa ^a,b   Siljamäki, Elina ^a,b   Riihilä, Pilvi ^a,b   Piipponen, Minna ^a,b   Kivisaari, Atte ^a,b   Kallajoki, Markku ^a   Grénman, Reidar ^a   Peltonen, Juha ^a   Peltonen, Sirkku ^a   Quint, Koen D ^c,d   Bavinck, Jan Nico Bouwes ^c   Kähäri, Veli Matti ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d DDL DIAGNOSTIC LABORATORY   (Netherlands)

Author keywords

AIM2; Cancer; Inflammasome; Keratinocyte; Skin

Indexed keywords

ABSENT IN MELANOMA 2 PROTEIN; COLLAGENASE 3; INFLAMMASOME; INTERSTITIAL COLLAGENASE; MESSENGER RNA; ONCOPROTEIN; UNCLASSIFIED DRUG; AIM2 PROTEIN, HUMAN; DNA BINDING PROTEIN;

ACTINIC KERATOSIS; AIM2 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE REGULATION; CELL DEATH; CELL INVASION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GRAFT RECIPIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RNA SEQUENCE; SKIN CANCER CELL LINE; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA CELL LINE; TUMOR INVASION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; DISEASE MODEL; GENE KNOCKDOWN; GENETICS; METABOLISM; PATHOLOGY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; INFLAMMASOMES; KERATINOCYTES; RNA, MESSENGER; SKIN NEOPLASMS;

EID: 85022194008     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.17573     Document Type: Article

References (38)

1. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002; 146: 1-6
2. Housman TS, Feldman SR, Williford PM, Fleischer AB, Jr., Goldman ND, Acostamadiedo JM, Chen GJ. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003; 48: 425-429
3. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, Coldiron BM. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010; 146: 283-287
4. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001; 344: 975-983
5. Kivisaari A, Kähäri VM. Squamous cell carcinoma of the skin: emerging need for novel biomarkers. World J Clin Oncol. 2013; 4: 85-90
6. Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest. 2012; 122: 464-472
7. Nissinen L, Farshchian M, Riihilä P, Kähäri VM. New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma. Cell Tissue Res. 2016; 365: 691-702
8. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003; 348: 1681-1691
9. Hameetman L, Commandeur S, Bavinck JN, Wisgerhof HC, de Gruijl FR, Willemze R, Mullenders L, Tensen CP, Vrieling H. Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients. BMC Cancer. 2013; 13: 58
10. Wisgerhof HC, Edelbroek JR, de Fijter JW, Haasnoot GW, Claas FH, Willemze R, Bavinck JN. Subsequent squamousand basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation. 2010; 89: 1231-1238
11. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature. 2012; 481: 278-286
12. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014; 157: 1013-1022
13. Dombrowski Y, Peric M, Koglin S, Kammerbauer C, Goss C, Anz D, Simanski M, Glaser R, Harder J, Hornung V, Gallo RL, Ruzicka T, Besch R, Schauber J. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med. 2011; 3: 82ra38
14. Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev. 2015; 265: 6-21
15. Beer HD, Contassot E, French LE. The inflammasomes in autoinflammatory diseases with skin involvement. J Invest Dermatol. 2014; 134: 1805-1810
16. Tervaniemi MH, Katayama S, Skoog T, Siitonen HA, Vuola J, Nuutila K, Sormunen R, Johnsson A, Linnarsson S, Suomela S, Kankuri E, Kere J, Elomaa O. NOD-like receptor signaling and inflammasome-related pathways are highlighted in psoriatic epidermis. Sci Rep. 2016; 6: 22745
17. Zhang W, Cai Y, Xu W, Yin Z, Gao X, Xiong S. AIM2 facilitates the apoptotic DNA-induced systemic lupus erythematosus via arbitrating macrophage functional maturation. J Clin Immunol. 2013; 33: 925-937
18. Santamaría D, Barrière C, Cerqueira A, Hunt S, Tardy C, Newton K, Cáceres JF, Dubus P, Malumbres M, Barbacid M. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007; 448: 811-815
19. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006; 72: 1605-1621
20. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420: 860-867
21. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, Hornung V, Vogel SN, Szomolanyi-Tsuda E, Fitzgerald KA. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010; 11: 395-402
22. de Koning HD, Bergboer JG, van den Bogaard EH, van Vlijmen-Willems IM, Rodijk-Olthuis D, Simon A, Zeeuwen PL, Schalkwijk J. Strong induction of AIM2 expression in human epidermis in acute and chronic inflammatory skin conditions. Exp Dermatol. 2012; 21: 961-964
23. Dihlmann S, Tao S, Echterdiek F, Herpel E, Jansen L, Chang-Claude J, Brenner H, Hoffmeister M, Kloor M. Lack of Absent in Melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients. Int J Cancer. 2014; 135: 2387-2396
24. Patsos G, Germann A, Gebert J, Dihlmann S. Restoration of absent in melanoma 2 (AIM2) induces G2/M cell cycle arrest and promotes invasion of colorectal cancer cells. Int J Cancer. 2010; 126: 1838-1849
25. Chen IF, Ou-Yang F, Hung JY, Liu JC, Wang H, Wang SC, Hou MF, Hortobagyi GN, Hung MC. AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. Mol Cancer Ther. 2006; 5: 1-7
26. Ponomareva L, Liu H, Duan X, Dickerson E, Shen H, Panchanathan R, Choubey D. AIM2, an IFN-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer. Mol Cancer Res. 2013; 11: 1193-1202
27. Choubey D, Walter S, Geng Y, Xin H. Cytoplasmic localization of the interferon-inducible protein that is encoded by the AIM2 (absent in melanoma) gene from the 200-gene family. FEBS Lett. 2000; 474: 38-42
28. Ludlow LE, Johnstone RW, Clarke CJ. The HIN-200 family: more than interferon-inducible genes? Exp Cell Res. 2005; 308: 1-17
29. Ala-aho R, Ahonen M, George SJ, Heikkilä J, Grénman R, Kallajoki M, Kähäri VM. Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo. Oncogene. 2004; 23: 5111-5123
30. Johansson N, Airola K, Grénman R, Kariniemi AL, Saarialho-Kere U, Kähäri VM. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol. 1997; 151: 499-508
31. de Koning HD, van Vlijmen-Willems IM, Zeeuwen PL, Blokx WA, Schalkwijk J. Absent in Melanoma 2 is predominantly present in primary melanoma and primary squamous cell carcinoma, but largely absent in metastases of both tumors. J Am Acad Dermatol. 2014; 71: 1012-1015
32. Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer. Cancer Immunol Res. 2017; 5: 94-99
33. Farshchian M, Nissinen L, Grènman R, Kähäri VM. Dasatinib promotes apoptosis of cutaneous squamous carcinoma cells by regulating activation of ERK1/2. Exp Dermatol. 2017; 26: 89-92
34. Riihilä P, Nissinen L, Farshchian M, Kivisaari A, Ala-aho R, Kallajoki M, Grénman R, Meri S, Peltonen S, Peltonen J, Kähäri VM. Complement factor I promotes progression of cutaneous squamous cell carcinoma. J Invest Dermatol. 2015; 135: 579-588
35. Riihilä PM, Nissinen LM, Ala-aho R, Kallajoki M, Grenman R, Meri S, Peltonen S, Peltonen J, Kähäri VM. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol. 2014; 134: 498-506
36. Farshchian M, Nissinen L, Siljamäki E, Riihilä P, Toriseva M, Kivisaari A, Ala-Aho R, Kallajoki M, Veräjänkorva E, Honkanen HK, Heljasvaara R, Pihlajaniemi T, Grénman R, et al. EphB2 promotes progression of cutaneous squamous cell carcinoma. J Invest Dermatol. 2015; 135: 1882-1892
37. Farshchian M, Kivisaari A, Ala-Aho R, Riihilä P, Kallajoki M, Grénman R, Peltonen J, Pihlajaniemi T, Heljasvaara R, Kähäri VM. Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma. Am J Pathol. 2011; 179: 1110-1119
38. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol. 1986, 31: 229-234